Company / Operating Cash Flow
Rein Therapeutics, Inc. Operating Cash Flow History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$22.3M
FY2025
5-year range
-$24.9M / -$19.8M
FY2021-FY2025
Trend
-12.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Cash Flow has fluctuated over the past 9 years, ranging from -$28M in FY2019 to -$12M in FY2017.
Based on SEC 10-K filings.
-$22M in FY2025.
Improved from -$25M to -$22M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 12.5% year-over-year.
- Peak operating cash flow was recorded in FY2017.
- Lowest operating cash flow in the period was in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.18 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$22.3M | -12.5% |
| FY2024 | -$19.8M | +20.3% |
| FY2023 | -$24.9M | -4.7% |
| FY2022 | -$23.8M | -16.0% |
| FY2021 | -$20.5M | +22.7% |
| FY2020 | -$26.5M | +5.2% |
| FY2019 | -$27.9M | -36.0% |
| FY2018 | -$20.5M | -75.3% |
| FY2017 | -$11.7M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026